17 Results for "

Treg differentiation

" in MedChemExpress (MCE) Product Catalog:
Products (17)

17 Results for "Treg differentiation" in MCE Product Catalog:

3
Isoallolithocholic acid
Isoallolithocholic acid
0 Images
3 Cited Publications
Cat. No.: HY-B0172A
CAS No.: 2276-93-9
Synonyms: 3β-Hydroxy-5α-cholanic acid
Target:  

Drug Derivative

Research Areas:  

Inflammation/Immunology

Isoallolithocholic acid (3β-Hydroxy-5α-cholanic acid), a derivative of Lithocholic acid (HY-10219), is a T cell regulator. Isoallolithocholic acid enhances regulatory T cells (Tregs) differentiation .
loading...
    loading...
View All Sizes
2
AZ084
AZ084
0 Images
2 Cited Publications
Cat. No.: HY-119217
CAS No.: 929300-19-6
Purity:  99.65%
Target:  

CCR

Research Areas:  

Inflammation/Immunology Endocrinology Cancer

AZ084 is a potent, selective, allosteric and oral active CCR8 allosteric antagonist, with a Ki of 0.9 nM. Has potential to treat asthma . AZ084 restrains the formation of the immunologically tolerant pre-metastatic niche (PMN) and tumor cells metastasis in lung by downregulating Treg differentiation. AZ084 can be used in studies of asthma and cancer .
loading...
    loading...
View All Sizes
1
Cusatuzumab
Cusatuzumab
0 Images
1 Cited Publications
Cat. No.: HY-P99014
CAS No.: 1864871-20-4
Synonyms: ARGX-110

Target:  

Fc Receptor (FcR) NF-κB

Research Areas:  

Inflammation/Immunology Cancer

Cusatuzumab (ARGX-110) is a selective competitive blocker targeting CD70 (with an equilibrium dissociation constant of 17 pM for binding to human CD70). Cusatuzumab also possesses enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. It is a humanized IgG1 monoclonal antibody, artificially synthesized through humanization and genetic engineering modifications (CH2 region mutation to enhance effector function). Cusatuzumab has a dual mechanism of action: firstly, it competitively blocks the interaction between CD70 and CD27, inhibiting the CD27-NF-κB signaling pathway, reducing regulatory T cell (Treg) activation and tumor cell proliferation; secondly, by enhancing binding to FcγRIIIa, it mediates ADCC and antibody-dependent cellular phagocytosis (ADCP), directly lysing CD70-positive tumor cells. Cusatuzumab can efficiently eliminate leukemia stem cells (LSCs), induce tumor cell differentiation and apoptosis, restore immune surveillance, and target CD70-positive tumors. Cusatuzumab is used in the study of acute myeloid leukemia (AML) .
loading...
    loading...
View All Sizes
1
Neomangiferin
Neomangiferin
0 Images
1 Cited Publications
Cat. No.: HY-N0723
CAS No.: 64809-67-2
Category:  

Xanthones Metabolic Disease Phenols Polyphenols 500 - Internal Server Error | MedChemExpress

Oops!

Sorry, Something went wrong on our server.
Our team has been notified and is working to fix the issue.